However, several tumor features have probably impacted treatment choices, since significant differences in the treatment groups could be noted, suggesting that patients with a more aggressive disease course with higher Ki67, elevated LDH, and SSTR negative tumors received FOLFOX, whereas TEM/CAP patients might have had a more indolent disease. This evidence concerns the gene MKI67 and neoplasm.